Innate Pharma (IPHA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Innate Pharma is expected to report Q2 2026 results before market open on September 17, 2026. Analysts project a loss of $0.2946 per share and revenue of approximately $6.35 million.
• IPHA shares opened at $1.95, compared with a 1-year range of $1.17 to $2.71. The stock’s 50-day and 200-day moving averages are $1.97 and $1.73, respectively.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and a $6.67 price target; several firms recently upgraded the stock or raised targets, including BTIG Research to $9.00 and HC Wainwright to $7.00.

Innate Pharma (NASDAQ:IPHA - Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Thursday, September 17th. Analysts expect Innate Pharma to announce earnings of ($0.2946) per share and revenue of $6.3530 million for the quarter. Individuals can check the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, September 17, 2026 at 9:00 AM ET.

Innate Pharma Price Performance

Shares of IPHA stock opened at $1.95 on Thursday. The stock has a 50-day moving average of $1.97 and a 200-day moving average of $1.73. Innate Pharma has a 1-year low of $1.17 and a 1-year high of $2.71.

Analysts Set New Price Targets

IPHA has been the topic of several recent analyst reports. Citigroup raised Innate Pharma from a "buy" rating to an "outperform" rating in a research note on Tuesday, August 11th. Leerink Partners upgraded shares of Innate Pharma from a "market perform" rating to an "outperform" rating and set a $4.00 price objective for the company in a research note on Tuesday, August 11th. HC Wainwright lifted their price objective on shares of Innate Pharma from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, August 10th. BTIG Research boosted their target price on shares of Innate Pharma from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Finally, UBS Group reissued a "buy" rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Innate Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.67.

Institutional Trading of Innate Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in shares of Innate Pharma in the fourth quarter valued at $162,000. OLD Mission Capital LLC acquired a new stake in shares of Innate Pharma in the 4th quarter worth about $50,000. Finally, Millennium Management LLC acquired a new stake in shares of Innate Pharma in the 4th quarter worth about $36,000. Institutional investors own 0.16% of the company's stock.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.